A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Detalles Bibliográficos
Autores principales: Weber, Jeffrey, Grob, Jean-Jaques, Margolin, Kim A, Ascierto, Paolo A, Sznol, Mario, Ott, Patrick A, Lejeune, Chantal, de Pril, Veerle, Ruisi, Mary M, Hodi, F Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645291/
http://dx.doi.org/10.1186/2051-1426-3-S2-P166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645291/
http://dx.doi.org/10.1186/2051-1426-3-S2-P166

Ejemplares similares